top of page

TargaZyme
Portfolio

Modulating the Immune system with Safe and Effective Medicines
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering more T-cells to to tumor sites from the vasculature, increasing the percentage of T-cells in the tumor micro-environment that express FASL, Granzyme B & Perforin, increasing the synapse formation between the T-cells and tumors, enabling increased intra-tumor penetration, and improving the cytoxicity of T-cells for increased cancer tumor killing.
bottom of page